Irvine Pharmaceutical Services has plans to significantly increase capacity over the course of this fiscal year that will double capacity for filling (both lyophilized and liquid), formulation, and biopharmaceutical development by 2Q14.   
 
As part of this initiative, the company incorporated its Avrio parenteral manufacturing facility into the Irvine brand in January. Irvine has since increased technical staff across most departments and plans to add an additional 40 employees during the next 12 months.
 
Dr. Assad J. Kazeminy, Irvine’s chief executive officer and founder, described the plans as “a three-prong initiative for aggressive yet stable growth, with more highly trained technical personnel, state-of-the-art instrumentation and increased capacity for formulation, biopharmaceuticals and raw material testing.”
 
“We have been building to this trajectory for the past five years,” Dr. Kazeminy said. “We are ‘just in time’ to meet the quickly expanding needs of the biopharmaceutical industry as it adjusts to an improving economy, mounting regulatory restrictions and faster-to-market demands.”